Skip to Main Content

Advertisement

Skip Nav Destination

Abstract OT3-3-05: Neurotoxicity characterization phase II randomized study of nab-paclitaxel versus conventional paclitaxel as first-line therapy of metastatic HER2-negative breast cancer. An ONSOCUR Study Group.

Cancer Res (2012) 72 (24_Supplement): OT3-3-05.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal